Results of surgical treatment for isolated recurrent ovarian cancer involving the liver
Summary. Objective: to investigate the effectiveness and factors that can influence on surgical treatment of isolated recurrent ovarian cancer involving the liver. Materials and methods: A retrospective analysis of medical documentation of ovarian cancer patients, who underwent surgical removal o...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2016-06-01
|
| Series: | Zaporožskij Medicinskij Žurnal |
| Subjects: | |
| Online Access: | http://zmj.zsmu.edu.ua/article/view/77001/73893 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251368966651904 |
|---|---|
| author | V. V. Boyko K. V. Kharchenko S. O. Savvi |
| author_facet | V. V. Boyko K. V. Kharchenko S. O. Savvi |
| author_sort | V. V. Boyko |
| collection | DOAJ |
| description | Summary. Objective: to investigate the effectiveness and factors that can influence on surgical treatment of isolated recurrent ovarian cancer involving the liver.
Materials and methods: A retrospective analysis of medical documentation of ovarian cancer patients, who underwent surgical removal of the recurrent tumors localized in the liver, performed in State Establishment «Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine» from January 2001 to December 2010 (n = 29).
Results. Overall survival increased significantly while disease-free interval (DFI) increase (after primary cytoreduction) and optimal secondary cytoreduction is achieved. Median overall survival for DFI <12 months was 13 months, 12-24 months – 41 months, > 24 months – 61 months (p <0,05). Performance of optimal secondary cytoreduction leads to increase of overall survival from 10 to 44 months (p <0,05). Median overall survival after secondary surgery was 41 months (95% CI; 6-62 months), median DFI – 26 months (95% CI; 3-42 months); 5-year survival rate was 37%. Serum CA-125, tumor size and number of lesions did not correlate with survival rates.
Conclusions. Recurrent ovarian cancer involving the liver should not be regarded solely as a result of hematogenous dissemination. Taking into account the biological characteristics of ovarian cancer, it can be the result of implantation spread of disease. Liver resection – aggressive, but effective, safe and affordable intervention. Indications should be individualized for patients with recurrent ovarian cancer. |
| format | Article |
| id | doaj-art-77b47f7f4eca4e03a859f8843bd4968e |
| institution | OA Journals |
| issn | 2306-4145 2310-1210 |
| language | English |
| publishDate | 2016-06-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Zaporožskij Medicinskij Žurnal |
| spelling | doaj-art-77b47f7f4eca4e03a859f8843bd4968e2025-08-20T01:57:55ZengZaporizhzhia State Medical and Pharmaceutical UniversityZaporožskij Medicinskij Žurnal2306-41452310-12102016-06-0138792Results of surgical treatment for isolated recurrent ovarian cancer involving the liverV. V. BoykoK. V. KharchenkoS. O. SavviSummary. Objective: to investigate the effectiveness and factors that can influence on surgical treatment of isolated recurrent ovarian cancer involving the liver. Materials and methods: A retrospective analysis of medical documentation of ovarian cancer patients, who underwent surgical removal of the recurrent tumors localized in the liver, performed in State Establishment «Zaitsev V.T. Institute of General and Emergency Surgery of the Academy of Medical Sciences of Ukraine» from January 2001 to December 2010 (n = 29). Results. Overall survival increased significantly while disease-free interval (DFI) increase (after primary cytoreduction) and optimal secondary cytoreduction is achieved. Median overall survival for DFI <12 months was 13 months, 12-24 months – 41 months, > 24 months – 61 months (p <0,05). Performance of optimal secondary cytoreduction leads to increase of overall survival from 10 to 44 months (p <0,05). Median overall survival after secondary surgery was 41 months (95% CI; 6-62 months), median DFI – 26 months (95% CI; 3-42 months); 5-year survival rate was 37%. Serum CA-125, tumor size and number of lesions did not correlate with survival rates. Conclusions. Recurrent ovarian cancer involving the liver should not be regarded solely as a result of hematogenous dissemination. Taking into account the biological characteristics of ovarian cancer, it can be the result of implantation spread of disease. Liver resection – aggressive, but effective, safe and affordable intervention. Indications should be individualized for patients with recurrent ovarian cancer.http://zmj.zsmu.edu.ua/article/view/77001/73893RecurrenceOvarian CancerSurgical TreatmentLiver |
| spellingShingle | V. V. Boyko K. V. Kharchenko S. O. Savvi Results of surgical treatment for isolated recurrent ovarian cancer involving the liver Zaporožskij Medicinskij Žurnal Recurrence Ovarian Cancer Surgical Treatment Liver |
| title | Results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| title_full | Results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| title_fullStr | Results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| title_full_unstemmed | Results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| title_short | Results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| title_sort | results of surgical treatment for isolated recurrent ovarian cancer involving the liver |
| topic | Recurrence Ovarian Cancer Surgical Treatment Liver |
| url | http://zmj.zsmu.edu.ua/article/view/77001/73893 |
| work_keys_str_mv | AT vvboyko resultsofsurgicaltreatmentforisolatedrecurrentovariancancerinvolvingtheliver AT kvkharchenko resultsofsurgicaltreatmentforisolatedrecurrentovariancancerinvolvingtheliver AT sosavvi resultsofsurgicaltreatmentforisolatedrecurrentovariancancerinvolvingtheliver |